Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Thrombocythaemia Myelofibrosis Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 25 Aug 16

Research and Markets has announced the addition of the "Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2016" drug pipelines to their offering.

This report provides comprehensive information on the therapeutic development for Thrombocythaemia Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocythaemia Myelofibrosis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Thrombocythaemia Myelofibrosis Overview
  3. Therapeutics Development
  4. Pipeline Products for Thrombocythaemia Myelofibrosis - Overview
  5. Pipeline Products for Thrombocythaemia Myelofibrosis - Comparative Analysis
  6. Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies
  7. Thrombocythaemia Myelofibrosis - Therapeutics under Investigation by Universities/Institutes
  8. Thrombocythaemia Myelofibrosis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Thrombocythaemia Myelofibrosis - Products under Development by Companies
  13. Thrombocythaemia Myelofibrosis - Products under Investigation by Universities/Institutes
  14. Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • JW Pharmaceutical Corporation
  • Nippon Shinyaku Co., Ltd.
  • Novartis AG
  • Pfizer Inc.

For more information about this drug pipelines visit

Related Topics: Leukemia Drugs

View source version on

Business Wire

Last updated on: 25/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.